Skip to content
Screener

Ocular Therapeutix OCUL Q1 2025 earnings

Reported May 5, 2025 · Before market open

Revenue$10.6MMiss by $2.5M
EPS-$0.37Miss by $0.08
Revenue estimate$13.1M
EPS estimate-$0.29

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$14.3M
EPS estimate-$0.36

Financials

Q1 2025

Income statement

See full
Revenue$10.7M-27.6%
Gross profit$9.4M-29.8%
Operating income-$63.9M-102%
Net income-$64.1M+1.2%
EPS (diluted)-$0.38+22.4%

Balance sheet

See full
Cash & equivalents$349.7M-27.6%
Total debt$76.2M+2.4%
Total equity$265.9M-34.8%
Total assets$405.9M-24.7%

Cash flow

See full
Operating cash flow-$44.7M-31.8%
CapEx$1.9M+658%
Free cash flow-$46.6M-36.5%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$1.17B-3.0%
Enterprise value$892.18M+12.5%
P/S19.5×-0.5×

Profitability

See full
Gross margin90.7%-0.3pp
Operating margin-342.2%-1,774pp
Net margin-323.1%+678pp
FCF margin-248.8%+608pp

Returns & leverage

See full
Return on equity-57.2%+2.2pp
Debt / equity0.3×+0.1×
Current ratio10.2×-11.2×

Segments

By segment

See full
Single Reportable$10.7M-27.6%

FAQ

When did Ocular Therapeutix report Q1 2025 earnings?
Ocular Therapeutix (OCUL) reported Q1 2025 earnings on May 5, 2025 before market open.
What were Ocular Therapeutix's Q1 2025 revenue and EPS?
Ocular Therapeutix reported revenue of $10.6M and eps of $-0.37 for Q1 2025.
Did Ocular Therapeutix beat estimates in Q1 2025?
Revenue missed the consensus estimate of $13.1M by $2.5M. EPS missed the consensus estimate of $-0.29 by $0.08.
How did Ocular Therapeutix's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 27.7% from $14.7M a year earlier and eps declined 54.2% from $-0.24.
Where can I find Ocular Therapeutix's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-044349) and the 10-Q periodic report (0001558370-25-006225) directly on SEC EDGAR. The filing index links above go to sec.gov.